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Abstract
The association of education, tobacco smoking, alcohol consumption, and interleukin-2 (IL-2 +114 and -384) and -6 (IL-6 -174) 
DNA polymorphisms with head and neck squamous cell carcinoma (HNSCC) was investigated in a cohort study of 445 subjects. 
IL-2 and IL-6 genotypes were determined by real-time PCR. Cox regression was used to estimate hazard ratios (HR) and 95% 
confidence intervals (95%CI) of disease-specific survival according to anatomical sites of the head and neck. Mean age was 56 
years and most patients were males (87.6%). Subjects with 5 or more years of schooling had better survival in larynx cancer. 
Smoking had no effect on HNSCC survival, but alcohol consumption had a statistically significant effect on larynx cancer. IL-2 
gene +114 G/T (HR = 0.52; 95%CI = 0.15-1.81) and T/T (HR = 0.22; 95%CI = 0.02-3.19) genotypes were associated with bet-
ter survival in hypopharynx cancer. IL-2 +114 G/T was a predictor of poor survival in oral cavity/oropharynx cancer and larynx 
cancer (HR = 1.32; 95%CI = 0.61-2.85). IL-2 -384 G/T was associated with better survival in oral cavity/oropharynx cancer (HR 
= 0.80; 95%CI = 0.45-1.42) and hypopharynx cancer (HR = 0.68; 95%CI = 0.21-2.20), but an inverse relationship was observed 
for larynx cancer. IL-6 -174 G/C was associated with better survival in hypopharynx cancer (HR = 0.68; 95%CI = 0.26-1.78) and 
larynx cancer (HR = 0.93; 95%CI = 0.42-2.07), and C/C reduced mortality in larynx cancer. In general, our results are similar 
to previous reports on the value of education, smoking, alcohol consumption, and IL-2 and IL-6 genetic polymorphisms for the 
prognosis of HNSCC, but the risks due to these variables are small and estimates imprecise. 
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Tumors of the oral cavity, pharynx and larynx, collec-
tively defined as head and neck cancer, are a significant 
cause of morbidity and mortality, with over 500,000 new 
cases estimated for 2008 worldwide (1). Annually about 
22,000 new cases are diagnosed in Brazil, the majority 
in the South and Southeast regions (2). Squamous cell 
carcinoma is the most frequent histological type. Prognosis 
varies according to anatomical subsites. The relative 5-year 
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survival rate is around 50-70%, considering all sites and 
clinical stages, and all forms of treatment (3). In Brazil, the 
5-year survival rate for oral and oropharyngeal cancer is 
still below 50% (4).
Prognostic factors, which have been examined in rela-
tion to head and neck cancer survival, include clinical tumor 
stage, patient education, tobacco smoking, and alcohol 
consumption (5-7). More recently, some genetic markers 
have been studied in relation to head and neck cancer 
survival, including gene polymorphisms related to invasion 
and metastasis, inflammation and DNA repair (8-10).
Interleukins (IL) are a type of cytokines, which are small 
secreted proteins related to the inflammation process and 
angiogenesis (11). IL-2 is an immunoregulatory cytokine 
and high serum levels of its receptor, sIL-2Rα, have been 
correlated with poor head and neck cancer survival and 
can be considered an independent prognostic biomarker 
in these tumors (12). IL-2 DNA polymorphisms have been 
recently associated with prostate tumor formation (13) and 
low risk of gastric cancer (14), but not with risk of chronic 
lymphocytic leukemia (15). Associations have also been 
identified between IL-6 DNA polymorphisms and the risk of 
colorectal, lung and oral cancer (16-18). However, investi-
gations of the role of interleukins in cancer prognosis are 
rare. IL-2 +114 and -384, and IL-6 -174 were not associated 
with prognosis of gastric cardia or esophageal cancer (19). 
IL-6 -174 has been correlated with poor survival in breast, 
bladder, and prostate cancer (20-22).
In this study, we addressed the role of education, tobacco 
smoking, alcohol consumption, and IL-2 +114 and -384, and 
IL-6 -174 genetic polymorphisms in the prognosis of head 
and neck squamous cell carcinoma (HNSCC).
Material and Methods
From November 1998 to December 2002, 586 individu-
als diagnosed with HNSCC were recruited at eight hospitals 
from three cities in Brazil (São Paulo, Goiânia, and Porto 
Alegre) and were followed up until June 30, 2005. The study 
was approved by the Ethics Committee of each clinical 
center and written informed consent was obtained from 
all participants. All head and neck cancer cases were con-
firmed by histology as squamous cell carcinoma. Using the 
10th revision of the International Classification of Diseases 
(ICD-10) (23), tumors were grouped into three categories, 
according to anatomical subsites, considering their distinct 
prognosis: oral cavity/oropharynx, hypopharynx, or larynx. 
The ICD-10 coding used for subsite classification was that 
used by Hashibe et al. (24): oral cavity/oropharynx (C00.3-
C00.9, C01.9, C02.0-C02.3, C02.4, C02.8, C02.9, C03.0, 
C03.1, C04.0, C04.1, C04.8, C04.9, C05.0, C05.1, C05.8, 
C05.9, C06.0-C06.2, C06.8, C06.9, C09.0, C09.1, C09.8, 
C09.9, C10.0-C10.4, C10.8, C10.9, C14.0, C14.2, and 
C14.8), hypopharynx (C12.9, C13.0-C13.2, C13.8, and 
C13.9), or larynx (C32.0-C32.3, C32.8, and C32.9).
Patient hospital records were reviewed to obtain addi-
tional information about tumor clinical stage and treatment, 
and patient vital status. Tumor clinical stage was classified 
according to the tumor-node-metastases system (TNM) (25) 
as clinical stage (CS) I to IV. As the effect of tumor clinical 
stage on head and neck cancer survival is well known, we 
only included patients with advanced clinical stages (CS III 
and IV). As a consequence, the sample size was restricted 
to 445 subjects. 
Information on patient vital status was also assessed by 
linking to population mortality and cancer registry databases. 
Cause of death was validated through death certificates 
obtained from the São Paulo State Death Registry (for 
patients from São Paulo city) and from the Population 
Cancer Registry of Goiânia (for patients from Goiânia). In 
Porto Alegre, death certificates were included in hospital 
medical records; these were also the only source of patient 
vital status information at that center. Of the 445 individuals, 
111 were alive and 267 had died by the end of the study, 
with 224 deaths being related to head and neck cancer, 
and 67 were lost during follow-up.
All patients underwent face-to-face interviews immedi-
ately after diagnosis by a trained interviewer who used a 
structured questionnaire to obtain information on variables, 
which could impact head and neck cancer survival, such 
as education, tobacco smoking, and alcohol consumption. 
Formal education was measured in years of schooling. 
Tobacco smoking was measured by calculating the aver-
age number of cigarette packs smoked per day multiplied 
Table 1. Primers for interleukin polymorphism genotyping.
Gene/SNP position Forward primer (5’-3’) Reverse primer (5’-3’)
IL-2 +114 Primers 5’-GCACCTACTTCAAGTTCTACAAAGAA-3’ 5’-AAAGGAAATATACTTACATTAATTCCATTCAAAATCATCTG-3’
rs 2069763 Probes 5’-ATCCAGCAGTAAATG-3’ 5’-TAAATCCAGAAGTAAATG-3’
IL-2 -384 Primers 5’-GCTCTTGTCCACCACAATATGCTAT-3’ 5’-GCCTTCTGTATGAAACAGTTTTTCCT-3’
rs 2069762 Probes 5’-ATTTTCTTTGTCATAAAACT-3’ 5’-TTTCTTTGTCCTAAAACT-3’
IL-6 -174 Primers 5’-GACGACCTAAGCTGCACTTTTC-3’ 5’-GGGCTGATTGGAAACCTTATTAAGATTG-3’
rs 1800795 Probes 5’-CTTTAGCATGGCAAGAC-3’ 5’-CTTTAGCATCGCAAGAC-3’
Source: Ref. 19. 
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by the number of years smoking (pack-years) (26). Alcohol 
consumption prior to head and neck cancer diagnosis was 
measured in grams of ethanol per milliliter per day (g etha-
nol/day), considering the equivalence of ethanol in different 
beverages: beer, wine, and spirits (27).
Blood DNA was extracted at the Institute of Tropical 
Medicine, University of São Paulo, using the Qiagen kit™ 
and genotyping procedures were conducted at the Cell 
Therapy Center Faculty of Medicine of Ribeirão Preto, 
University of São Paulo. Genetic polymorphisms were 
determined by real-time polymerase chain reaction (PCR) 
using TaqMan SNP genotyping assays. These assays 
included two locus-specific PCR primers that flank the 
single nucleotide polymorphism (SNP) of interest, and two 
allele-specific oligonucleotide TaqMan® probes (Applied 
Biosystems, USA). Each probe used a different fluorescent 
reporter dye at the 5’ end, and a non-fluorescent quencher 
with a minor groove binder (MGB) at the 3’ end. PCR primers 
amplify a specific locus on the genomic DNA template, and 
each fluorescent dye-labeled hybridization probe reports 
the presence of its associated allele in the DNA sample, 
as an allele-specific PCR, in a single tube (28). The primer 
design is unique and specific for the SNP, as assays are 
functionally tested against a small subset of genomic DNA 
by the supplier. All primers and probes were designed using 
the Assay-by-Design service offered by Applied Biosystems. 
These primers and probes are designed to be amplified 
under the following universal cycling conditions: 10 min at 
95°C, followed by 40 cycles of 94°C for 15 s and 60°C for 
1 min. All primers are depicted in Table 1. Genomic DNA 
obtained from whole blood samples was diluted at 1 ng/µL 
and 5.0 ng was used for each 15 µL real-time PCR using 
the TaqMan Master Mix (Applied Biosystems).
Statistical analysis was conducted using the Statisti-
cal Package for the Social Sciences (SPSS Inc., USA) 
and the STATA (Stata Corp., USA) software. Frequencies 
and percentages were used for categorical variables and 
means and standard deviations were calculated for con-
tinuous variables. Life tables were constructed for 1-, 3-, 
and 5-year survival according to anatomical site. Median 
follow-up was calculated for each site. Kaplan-Meier curves 
were constructed for each site and a log-rank test was used 
to compare these survival curves. At the end of follow-up, 
living patients, those dead from other cause (not head 
and neck cancer), and those lost during follow-up were 
considered censored.
Cox proportional hazards regression was used to 
estimate hazard ratios (HR) and the respective 95% 
confidence intervals (95%CI) for disease-specific survival 
including education (classified into three strata), tobacco 
smoking (continuous variable according to consumption 
in pack-years), alcohol consumption (continuous variable 
according to g ethanol/day), and interleukin genetic poly-
morphisms according to specific subsite adjusted for age 
and gender. 
Results
Patient characteristics are shown in Table 2. Most 
patients were diagnosed with oral/oropharynx cancer. 
Patient mean age was 56 years and males were predomi-
nant. Almost 70% of the patients had less than 5 years of 
Table 2. Patient distribution by tumor anatomical site, social and 
demographic characteristics, tobacco smoking, alcohol con-
sumption, tumor clinical stage, and genotypic frequencies of IL-2 
and IL-6 polymorphisms.
Cases (total = 445)
N %
Anatomical site
Oral/oropharynx 286 64.3
Hypopharynx 54 12.1
Larynx 105 23.6
Age (years)
≤50 143 32.1
51-60 154 34.6
61-70 111 24.9
>70 37 8.3
Mean (standard deviation)   56.0 (10.3)
Gender
Male 390 87.6
Female 55 12.4
Education (years)
<1 82 18.4
1-4 228 51.2
5 or more 135 30.3
Tobacco consumption (pack-years)
Mean (standard deviation)   40.1 (27.4)
Alcohol consumption (g ethanol/day)
Mean (standard deviation) 147.8 (182.3)
Clinical stage
CS III 106 23.8
CS IV 339 76.2
IL-2 +114a
G/G 190 47.3
G/T 181 45.0
T/T 31 7.7
IL-2 -384b
G/G 66 16.1
G/T 159 38.7
T/T 186 45.3
IL-6 -174c 
G/G 253 58.0
G/C 150 34.4
C/C 33 7.6
 a43 missing; b34 missing; c9 missing.
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schooling. Mean cumulative tobacco smoking 
was 40.1 pack-years and mean daily alcohol 
consumption was 147.8 g ethanol/day. Most 
cases were diagnosed at advanced tumor 
clinical stage (category CS IV). IL-2 +114 G/G, 
IL-2 -384 T/T, and IL-6 -174 G/G were the most 
common genotypes.
Table 3 shows post-diagnosis disease-
specific survival rates for the entire group of 
patients with overall HNSCC, and for specific 
subsites (oral cavity/oropharyngeal, hypopha-
ryngeal and laryngeal cancer) at 1, 3, and 5 
years. Figure 1 shows the survival curves for 
three HNSCC anatomical sites. Differences 
between the curves are clear (log-rank test, P = 0.001). The 
best median survival time was observed for larynx tumors 
and the poorest for hypopharynx tumors.
Table 4 shows adjusted HR’s for oral cavity/oropharynx, 
hypopharynx and larynx tumors according to education, 
tobacco smoking, alcohol consumption, IL-2 +114, IL-2 
-384, and IL-6 -174 adjusted for age and gender.
Higher education was positively associated with better 
survival for laryngeal cancer, but with poor survival for hy-
popharyngeal cancer. Tobacco smoking did not show any 
effect on survival in oral/oropharyngeal, hypopharyngeal, 
or laryngeal tumors.
IL-2 +114 G/T and T/T were associated with better 
prognosis in hypopharyngeal cancer. IL-2 -384 G/T showed 
better survival in oral cavity/oropharynx and hypopharynx 
tumors, but increased the risk of death in laryngeal cancer. 
IL-6 -174 C/C showed worse survival in oral cavity and 
hypopharyngeal cancer, but better survival in laryngeal 
cancer.
Discussion
Low socioeconomic status (SES) has been associated 
with the risk of head and neck cancer (29). The relationship 
between SES and disease prognosis is less well known. 
We observed different effects of educational levels on head 
and neck cancer, depending on tumor specific anatomical 
site. In oral cavity/oropharynx and hypopharyngeal tumors, 
the risk of death increased with more years of schooling, 
whereas in laryngeal cancer, it was associated with better 
survival. These results, however, were imprecise.
Tobacco smoking and alcohol consumption are well-
known risk factors for head and neck cancer, but the im-
plications of these two factors in disease prognosis are not 
completely clear. Some studies have identified an effect, 
although not statistically significant, of these variables on 
head and neck cancer (30,31). In our study, we observed 
that tobacco smoking had no effect on prognosis in oral cav-
ity/oropharynx, hypopharynx, or laryngeal cancer. Alcohol 
consumption showed a statistically significant association 
with poor survival in laryngeal cancer, but the HR (consid-
ering the increase of risk according to each g ethanol/day) 
was very close to 1. 
A statistically significant association was observed be-
tween high serum IL-2 levels and shorter survival time in 
head and neck cancer patients (32). In our study, we found 
that IL-2 +114 was associated with poor survival in oral 
cavity/oropharynx cancer, although amino acid sequence 
did not change (codon 38, CTG>CTT; Leu>Leu). Instead, 
this polymorphism was associated with increased survival 
in patients with hypopharyngeal tumors, while its effect was 
unclear in laryngeal cancer. The IL-2 polymorphism -384 T/T 
was associated with low survival in all anatomical subsites 
and has been reported to show lower IL-2 levels compared 
to the G allele, although there are many conflicting data 
showing opposite results, which indicate that other factors 
may contribute to the effect of this polymorphism on IL-2 
expression levels (33). 
Some studies have found an association between IL-6 
Figure 1. Survival of patients with head and neck squamous cell 
carcinoma related to specific anatomical sites: oral cavity, hypo-
pharynx and larynx. Log-rank test for equality survival curves hy-
pothesis (Kaplan-Meier or product limit estimator).
Table 3. Median survival time and probability of survival 1, 3, and 5 years after 
diagnosis for head and neck squamous cell carcinoma (HNSCC) and accord-
ing to specific subsite.
Cumulative survival proportion Median survival 
time (months)
1 year 3 years 5 years
HNSCC 0.71 0.50 0.39 36.59
Oral cavity/oropharynx 0.69 0.48 0.37 30.09
Hypopharynx 0.59 0.33 0.27 18.69
Larynx 0.84 0.67 0.52 67.86
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-174 genetic polymorphisms and the risk of prostate, col-
orectal, and lung tumors (15-17). Few studies have found 
IL-6 -174 as a worse prognostic factor in breast, bladder, 
and prostate cancer (20-22), principally with the presence of 
the C allele. In our study, IL-6 -174 G/C and G/G genotypes 
were associated with reduced mortality in patients with oral 
and hypopharynx cancer. Moreover, the same genotypes 
were associated with a better survival in larynx cancer. It 
has been reported that G/G homozygotes produce higher 
levels of serum IL-6 when compared to C/G heterozygotes 
or C/C homozygotes (G/G>G/C>C/C) (34).
Some limitations of our study should be considered, 
such as sample size. Even though the total sample was 
relatively large, 445, when tumors were stratified by ana-
tomical origin, samples were reduced in size limiting the 
power of this study. Also, we were only able to genotype 
IL-2 +114 and IL-2 -384 polymorphisms in 90.3 and 92.4% 
of our sample, respectively. This affects the precision of our 
results, especially those related to genetic polymorphisms. 
A second possible limitation that we should not ignore 
was related to human papillomavirus (HPV). The pres-
ence of HPV infection may alter tumor profile and could 
have some implications in outcome. Individuals with HPV 
infection appear to have increased survival in oral cancer, 
but the reasons for this are unclear (35,36). A recent study 
on a group of patients enrolled in a randomized clinical 
trial has suggested an association with HPV-positivity as 
an independent prognostic factor among patients with 
oropharyngeal cancer (37). Moreover, in a recent report, 
the anti-apoptotic effect of HPV E6 expression was found 
to be mediated in part by up-regulation of osteoprotegerin 
and IL-6 in cutaneous squamous cell carcinoma (38). In a 
Table 4. Cox proportional hazards model for disease-specific survival according to the study variables.
Variable Oral cavity/oropharyngeal [adjusted HR (95%CI); P]
Hypopharyngeal
[adjusted HR (95%CI); P]
Laryngeal
[adjusted HR (95%CI); P]
Age (years)
≤50 1.00   1.00 1.00
51-60 1.03 (0.66-1.61); 0.88   1.09 (0.24-4.90); 0.91 0.63 (0.22-1.81); 0.39
61-70 1.34 (0.78-2.31); 0.28   2.00 (0.33-12.04); 0.46 1.22 (0.44-3.35); 0.71
>70 1.40 (0.61-3.20); 0.42 13.09 (1.37-125.12); 0.03 1.03 (0.22-4.79); 0.97
Gender
Female 1.00 NA 1.00
Male 1.19 (0.66-2.14); 0.57 2.50 (0.45-13.85); 0.29
Education (years)
<1 1.00   1.00 1.00
1-4 1.10 (0.63-1.93); 0.74   2.44 (0.53-11.20); 0.25 0.70 (0.22-2.24); 0.55
≥5 1.16 (0.61-2.20); 0.64   4.86 (0.56-42.30); 0.15 0.39 (0.10-1.53); 0.18
Smokinga 
Pack-years 1.00 (0.99-1.01); 0.51   1.00 (0.97-1.01); 0.45 1.00 (0.98-1.01); 0.41
Alcohol consumptionb
g ethanol/day 1.00 (0.99-1.00); 0.87   1.00 (0.99-1.00); 0.78 1.00 (1.00-1.01); 0.01
IL-2 +114
G/G 1.00   1.00 1.00
G/T 1.07 (0.72-1.57); 0.75   0.52 (0.15-1.81); 0.31 1.32 (0.61-2.85); 0.48
T/T 1.14 (0.58-2.23); 0.70   0.22 (0.02-3.19); 0.27 0.86 (0.15-4.80); 0.86
IL-2 -384
G/G 1.00   1.00 1.00
G/T 0.80 (0.45-1.42); 0.45   0.68 (0.21-2.20); 0.52 2.42 (0.71-8.30); 0.16
T/T 1.11 (0.64-1.93); 0.71   1.95 (0.52-7.37); 0.32 1.32 (0.39-4.47); 0.66
IL-6 -174
G/G 1.00   1.00 1.00
G/C 1.00 (0.68-1.49); 0.99   0.68 (0.26-1.78); 0.43 0.93 (0.42-2.07); 0.86
C/C 1.23 (0.69-2.18); 0.48   3.33 (0.51-23.01); 0.21 0.12 (0.01-1.52); 0.10
HR = hazard ratio; 95%CI = 95% confidence interval; NA = not available; aPack-years = number of cigarette 
packs smoked per day versus number of years of smoking; HR calculated for each pack-year increase. bHR 
calculated for each g ethanol/day increase.
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case-control study on women with cervical neoplasias, the 
authors showed that the level of E7-induced IL-2 production 
from the lymphocytes of patients with HPV 16 clearance was 
inversely correlated with the time relative to the last HPV 
DNA + test (39). In another study on women with cervical 
and vulvar cancer, the results suggested an increased risk 
of cancer among smokers modified by genetic variation in 
IL-2, cigarette components and decreased IL-2 levels (40). 
Confounding effects from tobacco use and tumor clinical 
stage at diagnosis have not been ruled out as potential 
reasons for the association between HPV and survival. 
In addition, we assumed that treatment was similar for 
all patients with head and neck cancer, but this could be 
an important confounding variable in studies on cancer 
survival. These limitations argue the case for a prudent 
interpretation of our results.
Overall, our study revealed the same inconsistent 
results as some earlier reports on the prognostic value of 
environmental factors, such as education, tobacco smok-
ing, and alcohol consumption, as well as IL-2 and IL-6 gene 
polymorphisms in HNSCC.
Acknowledgments
Research supported by FAPESP (#2001/01768-2 and 
#2005/50832-6) and the European Commission (#IC18-
CT97-022).
 1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. 
GLOBOCAN 2008, Cancer incidence and mortality world-
wide: IARC CancerBase No. 10. http://globocan.iarc.fr. 
 2. Instituto Nacional de Câncer (INCA). Coordenação de 
prevenção e vigilância de câncer. Secretaria de Atenção à 
Saúde. Ministério da Saúde. Estimativas 2008. Incidência 
de câncer no Brasil. Rio de Janeiro: INCA; 2007.
 3. Stewart BW, Kleihues P. World cancer report. Lyon: IARC 
Press; 2003.
 4. Carvalho AL, Ikeda MK, Magrin J, Kowalski LP. Trends of 
oral and oropharyngeal cancer survival over five decades in 
3267 patients treated in a single institution. Oral Oncol 2004; 
40: 71-76.
 5. de Graeff A, de Leeuw Jr, Ros WJ, Hordijk GJ, Blijham GH, 
Winnubst JA. Sociodemographic factors and quality of life as 
prognostic indicators in head and neck cancer. Eur J Cancer 
2001; 37: 332-339.
 6. Teppo H, Alho OP. Comorbidity and diagnostic delay in can-
cer of the larynx, tongue and pharynx. Oral Oncol 2009; 45: 
692-695.
 7. Dikshit RP, Boffetta P, Bouchardy C, Merletti F, Crosignani 
P, Cuchi T, et al. Lifestyle habits as prognostic factors in sur-
vival of laryngeal and hypopharyngeal cancer: a multicentric 
European study. Int J Cancer 2005; 117: 992-995.
 8. Chiang YY, Tsai MH, Lin TY, Chiang IP. Expression profile 
of metastasis-related genes in invasive oral cancers. Histol 
Histopathol 2008; 23: 1213-1222.
 9. Shimizu Y, Kondo S, Shirai A, Furukawa M, Yoshizaki T. A 
single nucleotide polymorphism in the matrix metallopro-
teinase-1 and interleukin-8 gene promoter predicts poor 
prognosis in tongue cancer. Auris Nasus Larynx 2008; 35: 
381-389.
10. Hopkins J, Cescon DW, Tse D, Bradbury P, Xu W, Ma C, et 
al. Genetic polymorphisms and head and neck cancer out-
comes: a review. Cancer Epidemiol Biomarkers Prev 2008; 
17: 490-499.
11. Serefoglou Z, Yapijakis C, Nkenke E, Vairaktaris E. Genetic 
association of cytokine DNA polymorphisms with head and 
neck cancer. Oral Oncol 2008; 44: 1093-1099.
12. Tartour E, Mosseri V, Jouffroy T, Deneux L, Jaulerry C, 
Brunin F, et al. Serum soluble interleukin-2 receptor concen-
trations as an independent prognostic marker in head and 
neck cancer. Lancet 2001; 357: 1263-1264.
13. Wu HC, Chang CH, Wan L, Wu CI, Tsai FJ, Chen WC. IL-2 
gene C/T polymorphism is associated with prostate cancer. 
J Clin Lab Anal 2006; 20: 245-249.
14. Wu J, Lu Y, Ding YB, Ke Q, Hu ZB, Yan ZG, et al. Promoter 
polymorphisms of IL-2, IL4, and risk of gastric cancer in a 
high-risk Chinese population. Mol Carcinog 2009; 48: 626-
632.
15. Ennas MG, Moore PS, Zucca M, Angelucci E, Cabras MG, 
Melis M, et al. Interleukin-1B (IL1B) and interleukin-6 (IL-6) 
gene polymorphisms are associated with risk of chronic 
lymphocytic leukaemia. Hematol Oncol 2008; 26: 98-103.
16. Belluco C, Olivieri F, Bonafe M, Giovagnetti S, Mammano 
E, Scalerta R, et al. -174 G>C polymorphism of interleukin 
6 gene promoter affects interleukin 6 serum level in patients 
with colorectal cancer. Clin Cancer Res 2003; 9: 2173-
2176.
17. Colakogullari M, Ulukaya E, Yilmaztepe OA, Aymak F, 
Basturk B, Ursavas A, et al. The involvement of IL-10, IL-6, 
IFN-gamma, TNF-alpha and TGF-beta gene polymorphisms 
among Turkish lung cancer patients. Cell Biochem Funct 
2008; 26: 283-290.
18. Vairaktaris E, Yapijakis C, Serefoglou Z, Avgoustidis D, 
Critselis E, Spyridonidou S, et al. Gene expression poly-
morphisms of interleukins-1 beta, -4, -6, -8, -10, and tumor 
necrosis factors-alpha, -beta: regression analysis of their 
effect upon oral squamous cell carcinoma. J Cancer Res 
Clin Oncol 2008; 134: 821-832.
19. Savage SA, Abnet CC, Haque K, Mark SD, Qiao YL, Dong 
ZW, et al. Polymorphisms in interleukin-2, -6, and -10 are 
not associated with gastric cardia or esophageal cancer in a 
high-risk Chinese population. Cancer Epidemiol Biomarkers 
Prev 2004; 13: 1547-1549.
20. DeMichele A, Gray R, Horn M, Chen J, Aplenc R, Vaughan 
WP, et al. Host genetic variants in the interleukin-6 promoter 
predict poor outcome in patients with estrogen receptor-
positive, node-positive breast cancer. Cancer Res 2009; 69: 
4184-4191.
21. Leibovici D, Grossman HB, Dinney CP, Millikan RE, Lerner 
S, Wang Y, et al. Polymorphisms in inflammation genes and 
References
1012 R.V.M. López et al.
www.bjournal.com.brBraz J Med Biol Res 44(10) 2011
bladder cancer: from initiation to recurrence, progression, 
and survival. J Clin Oncol 2005; 23: 5746-5756.
22. Pierce BL, Biggs ML, DeCambre M, Reiner AP, Li C, Fitzpat-
rick A, et al. C-reactive protein, interleukin-6, and prostate 
cancer risk in men aged 65 years and older. Cancer Causes 
Control 2009; 20: 1193-1203.
23. World Health Organization. International statistical clas-
sification of diseases and related health problems. 10th 
revision. Geneva: World Health Organization; 2004.
24. Hashibe M, Brennan P, Benhamou S, Castellsague X, Chen 
C, Curado MP, et al. Alcohol drinking in never users of to-
bacco, cigarette smoking in never drinkers, and the risk of 
head and neck cancer: pooled analysis in the International 
Head and Neck Cancer Epidemiology Consortium. J Natl 
Cancer Inst 2007; 99: 777-789.
25. American Joint Committee on Cancer. AJCC staging manual 
for cancer. 5th edn. Philadelphia: Lippincott-Raven; 1997.
26. International Agency for Research on Cancer (IARC). Tobac-
co smoking. IARC Monogr 36. Lyon: IARC Press; 1986.
27. International Agency for Research on Cancer (IARC). Alco-
hol drinking. IARC Monogr 33. Lyon: IARC Press; 1988.
28. De La Vega FM, Lazaruk KD, Rhodes MD, Wenz MH. As-
sessment of two flexible and compatible SNP genotyping 
platforms: TaqMan SNP Genotyping Assays and the SNPlex 
Genotyping System. Mutat Res 2005; 573: 111-135.
29. Conway DI, Petticrew M, Marlborough H, Berthiller J, Hashi-
be M, Macpherson LM. Socioeconomic inequalities and oral 
cancer risk: a systematic review and meta-analysis of case-
control studies. Int J Cancer 2008; 122: 2811-2819.
30. Nguyen-Tan PF, Le QT, Quivey JM, Singer M, Terris DJ, 
Goffinet DR, et al. Treatment results and prognostic factors 
of advanced T3-4 laryngeal carcinoma: the University of 
California, San Francisco (UCSF) and Stanford University 
Hospital (SUH) experience. Int J Radiat Oncol Biol Phys 
2001; 50: 1172-1180.
31. Boffetta P, Merletti F, Faggiano F, Migliaretti G, Ferro G, 
Zanetti R, et al. Prognostic factors and survival of laryngeal 
cancer patients from Turin, Italy. A population-based study. 
Am J Epidemiol 1997; 145: 1100-1105.
32. El Houda Agueznay N, Badoual C, Hans S, Gey A, Vingert 
B, Peyrard S, et al. Soluble interleukin-2 receptor and 
metalloproteinase-9 expression in head and neck cancer: 
prognostic value and analysis of their relationships. Clin Exp 
Immunol 2007; 150: 114-123.
33. Vandenbroeck K. Cytokine gene polymorphisms in multifac-
torial conditions. Boca Raton: CRC Press; 2006.
34. Lagmay JP, London WB, Gross TG, Termuhlen A, Sullivan N, 
Axel A, et al. Prognostic significance of interleukin-6 single 
nucleotide polymorphism genotypes in neuroblastoma: 
rs1800795 (promoter) and rs8192284 (receptor). Clin Can-
cer Res 2009; 15: 5234-5239.
35. Fakhry C, Westra WH, Li S, Cmelak A, Ridge JA, Pinto H, 
et al. Improved survival of patients with human papilloma-
virus-positive head and neck squamous cell carcinoma in a 
prospective clinical trial. J Natl Cancer Inst 2008; 100: 261-
269.
36. Smith EM, Wang D, Rubenstein LM, Morris WA, Turek LP, 
Haugen TH. Association between p53 and human papillo-
mavirus in head and neck cancer survival. Cancer Epidemiol 
Biomarkers Prev 2008; 17: 421-427.
37. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, 
Nguyen-Tan PF, et al. Human papillomavirus and survival 
of patients with oropharyngeal cancer. N Engl J Med 2010; 
363: 24-35.
38. Tomlins C, Storey A. Cutaneous HPV5 E6 causes increased 
expression of Osteoprotegerin and Interleukin 6 which con-
tribute to evasion of UV-induced apoptosis. Carcinogenesis 
2010; 31: 2155-2164.
39. de Gruijl TD, Bontkes HJ, Walboomers JM, Stukart MJ, 
Doekhie FS, Remmink AJ, et al. Differential T helper cell re-
sponses to human papillomavirus type 16 E7 related to viral 
clearance or persistence in patients with cervical neoplasia: 
a longitudinal study. Cancer Res 1998; 58: 1700-1706.
40. Hussain SK, Madeleine MM, Johnson LG, Du Q, Malkki 
M, Wilkerson HW, et al. Cervical and vulvar cancer risk in 
relation to the joint effects of cigarette smoking and genetic 
variation in interleukin 2. Cancer Epidemiol Biomarkers Prev 
2008; 17: 1790-1799.
